Literature DB >> 9130609

Post-transplant EBV induced lymphoproliferative disorders.

K G Lucas1, K E Pollok, D J Emanuel.   

Abstract

Epstein Barr virus induced lymphoproliferative disease (EBV-LPD) is a heterogeneous disorder, ranging from polyclonal lymphoproliferations to malignant lymphoma, typically seen in individuals with inadequate cellular immunity to EBV. The diagnosis of EBV-LPD following transplant requires a high index of suspicion in those patients at risk. Unlike organ transplant patients, in whom lymphomas are generally of host origin and respond to decreases in immunosuppression, bone marrow transplant recipients have donor origin tumors that are not as responsive to conservative treatment modalities. For the latter group, adoptive immunotherapy with donor lymphocytes is the treatment of choice and generally results in complete eradication of these tumors. Whether adoptive immunotherapy can be used for EBV-LPD in patients following organ transplantation is currently being investigated.

Entities:  

Mesh:

Year:  1997        PMID: 9130609     DOI: 10.3109/10428199709042491

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.

Authors:  D J Von Seggern; S Huang; S K Fleck; S C Stevenson; G R Nemerow
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 2.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 3.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

4.  Successful treatment of a patient with Epstein-Barr virus-positive B-cell lymphoproliferative disorder resembling post-transplant lymphoproliferative disorder using single-agent rituximab.

Authors:  Norman I Maldonado; Fernando Cabanillas; Elaine S Jaffe; Mark Raffeld; Luis Lozada
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

5.  Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.

Authors:  W J Jabs; H Hennig; M Kittel; K Pethig; F Smets; P Bucsky; H Kirchner; H J Wagner
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 6.  Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.

Authors:  Albert Faye; Etienne Vilmer
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.

Authors:  Yoshinari Kawabata; Makoto Hirokawa; Yoshinobu Saitoh; Shigeki Kosugi; Tomoko Yoshioka; Masumi Fujishima; Naohito Fujishima; Yoshihiro Kameoka; Hirobumi Saitoh; Masaaki Kume; Naoto Takahashi; Ken-ichi Sawada
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

8.  Double-step PCR assay to quantify Epstein-Barr viral load in peripheral blood.

Authors:  Massimiliano Bergallo; Chiara Merlino; Roberta Daniele; Franca Sinesi; Mara Fumagalli; Alessandro Negro Ponzi; Rossana Cavallo
Journal:  Mol Biotechnol       Date:  2004-07       Impact factor: 2.695

Review 9.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans.

Authors:  Elizabeth M Parzych; Hua Li; Xiangfan Yin; Qin Liu; Te-Lang Wu; Gregory M Podsakoff; Katherine A High; Matthew H Levine; Hildegund C J Ertl
Journal:  Hum Gene Ther       Date:  2013-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.